Published: September 2026
Medically reviewed by:
Mercè Tena Campos, Scientific Affairs Manager
What labs should know about risk in SLE and SSc
Antiphospholipid antibodies (aPL) are clinically relevant to biomarkers in connective tissue diseases, particularly in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). For laboratories, understanding the clinical value of aPL testing supports physicians in identifying patients with connective tissue disease (CTD) who require risk assessment for renal injury, thrombosis, and pregnancy-related complications.1-4
What are antiphospholipid antibodies
aPL are a heterogeneous group of autoantibodies, including lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti-ß2 glycoprotein- I antibody (anti-ß2GPI). These are common biomarkers for the antiphospholipid syndrome (APS), but also associated with other CTD like SLE.2
aPL in systemic lupus erythematosus
aPL are found to be associated with thrombocytopenia, hemolytic anemia, arteriovenous thrombosis and recurrent miscarriage in SLE patients. A 2026 systemic literature review and meta-analysis evaluated the association of aPL-positivity with renal damage across 70 studies with over 10,000 SLE patients.2
Key findings:
aPL-positivity is associated with an increased risk of lupus nephritis
LA-positive SLE patients had approximately two-fold higher odds of renal manifestations than LA-negative SLE patients (Odd ratio: 2.43)
aCL-positive SLE patients had approximately 50% higher odds of renal manifestations than aCL-negative SLE patients (Odd ratio: 1.71)
Pooled study conclusion:
- The authors reported that aPL positivity was associated with a higher risk of lupus nephritis and aPL may support renal injury risk stratification and monitoring in SLE patients.
- The authors found aPL promotes nephritis through inducing renal vascular thrombosis and immune dysregulation.
- More clinical studies are required to meet the unmet need of determining the roles of aPL and their different isotypes in kidney injury of SLE patients.
aPL in systemic sclerosis
A French research group in Lille conducted a cross-sectional study, systematic review and meta-analysis in 2014-2016, aimed to determine the worldwide prevalence of aPL in SSc patients. The study pooled data from 24 studies with over 3000 SSc patients. They found a strong relevance of aPL especially for aCL and aß2GPI in SSc patients.1
Similarly, the recent German S2k guideline for SSc diagnosis and therapy also included aPL as biomarkers for SSc lab testing. They indicated a higher aPL antibody titer is association with risk in renal crisis and a negative effect in family planning.4
Key findings from the multivariant study:1
Overall pooled prevalence of aPL seropositivity in SSc patients: 14%
Prevalence of aCL seropositivity: 9%, strongly associated with venous thrombosis and pulmonary arterial hypertension
Prevalence of aß2GPI positivity: 9%, strongly associated with higher risk of miscarriage
Summary of the German S2k Guideline:4
- The guideline recommends considering aPL tsting in SSc patients when renal crisis is clinically suspected and in the context of family planning.
Broader clinical impact of aPL in connective tissue diseases
In addition to SLE and SSc, a systematic review in 2021 evaluated the prevalence of aPL retrospectively in autoimmune rheumatic and musculoskeletal diseases (RMDs), including SScs, mixed connective tissue disease (MCTD), undifferentiated connective tissue disease (UCTD), Sjörgen’s syndrome (SS), ANCA associated vasculitides (AAV) and Rheumatoid Arthritis (RA). The study pooled data from 20 studies with over 3000 patients.3
Key findings:
aPL can be detected in up to 1/3 of RMDs patients, especially in SSc
Overall median prevalence of aPL-positive in RMDs patients: 14.05%
Prevalence of aCL isotypes in RMDs patients: IgG: 18.75%; IgM: 20.92%
Prevalence of aß2GPI isotypes in RMDs patients: IgG: 25%; IgM: 22.52%
Prevalence of aPL in SSc patients: 14.05%
Prevalence of aCL IgG in aPL-positive SSc patients: 35.48%
Pooled study conclusion:3
- The authors recommend considering aPL screening in autoimmune RMDs in selected scenarios such as family planning and thrombosis.
- Except for SLE, the authors do not suggest routine aPL screening for most RMDs.
How aPL supports risk stratification
Based on the reported aPL prevalence and associated clinical manifestations in SLE and SSc, aPL testing may provide additional clinical value by:
- Support risk stratification for renal injury in SLE patients and renal crisis in SSc patients.2,4
- Supporting the assessment in MCTD, UCTD and SSc patients in selected clinical circumstances, including pregnancy planning and suspected thrombosis.3,4
Thermo Fisher offer antiphospholipid antibodies testing and testings for broader connective tissue diseases, learn more about it through EliA™ portfolio.